Loading…
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Expressing support for changes to the CREATES Act (S. 340) and Fair Access for Safe and timely (FAST) Generics Act (H.R. 985)
A bill to promote competition in the market for drugs and biological products by facilitating the timely entry of lower-cost generic and biosimilar versions of those drugs and biological products.
Client: CELGENE CORPORATION · Firm: COVINGTON & BURLING LLP
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
CELGENE CORPORATION via COVINGTON & BURLING LLP
2019 · first_quarter · Q1
Expressing support for changes to the CREATES Act (S. 340) and Fair Access for Safe and timely (FAST) Generics Act (H.R. 985)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CELGENE CORPORATION via COVINGTON & BURLING LLP
2018 · third_quarter · Q3
Source: Senate LDA
Expressing support for changes to the CREATES Act (S. 340) and Fair Access for Safe and timely (FAST) Generics Act (H.R. 985)
Expressing support for changes to the CREATES Act (H.R. 2212, S. 974) and Fair Access for Safe and Timely (FAST) Generics Act (H.R. 2051).
Expressing support for changes to the CREATES Act (H.R. 2212, S. 974) and Fair Access for Safe and Timely (FAST) Generics Act (H.R. 2051). Analyzing the impact of SOUND Disposal and Packaging Act (HR 5687), the Opioid Crisis Response Act of 2018 (S. 2680), and the Stop Counterfeit Drugs by Regulating and Enhancing Enforcement Now Act" (the "SCREEN Act"), H.R. 5228.
Expressing support for changes to the CREATES Act (H.R. 2212, S. 974) and Fair Access for Safe and Timely (FAST) Generics Act (H.R. 2051).
Expressing support for changes to the CREATES Act (H.R. 2212, S. 974) and Fair Access for Safe and Timely (FAST) Generics Act (H.R. 2051).
Expressing support for changes to the CREATES Act (H.R. 2212, S. 974) and Fair Access for Safe and Timely (FAST) Generics Act (H.R. 2051). Analyzing the impact of SOUND Disposal and Packaging Act (HR 5687), the Opioid Crisis Response Act of 2018 (S. 2680), and the Stop Counterfeit Drugs by Regulating and Enhancing Enforcement Now Act" (the "SCREEN Act"), H.R. 5228.
Expressing support for changes to the CREATES Act (H.R. 2212, S. 974) and Fair Access for Safe and Timely (FAST) Generics Act (H.R. 2051).
Expressing support for changes to the CREATES Act (H.R. 2212, S. 974) and Fair Access for Safe and Timely (FAST) Generics Act (H.R. 2051). Analyzing the impact of SOUND Disposal and Packaging Act (HR 5687), the Opioid Crisis Response Act of 2018 (S. 2680), and the Stop Counterfeit Drugs by Regulating and Enhancing Enforcement Now Act" (the "SCREEN Act"), H.R. 5228.
SOUND Disposal and Packaging Act
Client: CELGENE CORPORATION · Firm: COVINGTON & BURLING LLP
Expressing support for changes to the CREATES Act (H.R. 2212, S. 974) and Fair Access for Safe and Timely (FAST) Generics Act (H.R. 2051). Analyzing the impact of SOUND Disposal and Packaging Act (HR 5687), the Opioid Crisis Response Act of 2018 (S. 2680), and the Stop Counterfeit Drugs by Regulating and Enhancing Enforcement Now Act" (the "SCREEN Act"), H.R. 5228.
Opioid Crisis Response Act of 2018
Client: CELGENE CORPORATION · Firm: COVINGTON & BURLING LLP
Expressing support for changes to the CREATES Act (H.R. 2212, S. 974) and Fair Access for Safe and Timely (FAST) Generics Act (H.R. 2051). Analyzing the impact of SOUND Disposal and Packaging Act (HR 5687), the Opioid Crisis Response Act of 2018 (S. 2680), and the Stop Counterfeit Drugs by Regulating and Enhancing Enforcement Now Act" (the "SCREEN Act"), H.R. 5228.
Creating and Restoring Equal Access to Equivalent Samples Act of 2018
Client: CELGENE CORPORATION · Firm: COVINGTON & BURLING LLP
Expressing support for changes to the CREATES Act (H.R. 2212, S. 974) and Fair Access for Safe and Timely (FAST) Generics Act (H.R. 2051).
Creating and Restoring Equal Access to Equivalent Samples Act of 2018
Client: CELGENE CORPORATION · Firm: COVINGTON & BURLING LLP
Expressing support for changes to the CREATES Act (H.R. 2212, S. 974) and Fair Access for Safe and Timely (FAST) Generics Act (H.R. 2051).
Creating and Restoring Equal Access to Equivalent Samples Act of 2018
Client: CELGENE CORPORATION · Firm: COVINGTON & BURLING LLP
Expressing support for changes to the CREATES Act (H.R. 2212, S. 974) and Fair Access for Safe and Timely (FAST) Generics Act (H.R. 2051). Analyzing the impact of SOUND Disposal and Packaging Act (HR 5687), the Opioid Crisis Response Act of 2018 (S. 2680), and the Stop Counterfeit Drugs by Regulating and Enhancing Enforcement Now Act" (the "SCREEN Act"), H.R. 5228.
Expressing support for changes to the CREATES Act (S. 3056), Fair Access for Safe and Timely (FAST) Generics Act (H.R. 2051), Lower Drug Costs through Competition Act (H.R. 749) and Senate counterpart (S. 297, Increasing Competition in Pharmaceuticals Act), and Affordable and Safe Prescription Drug Importation Act (S. 469).
Expressing support for changes to the CREATES Act (H.R. 2212, S. 974) and Fair Access for Safe and Timely (FAST) Generics Act (H.R. 2051).
Expressing support for changes to the CREATES Act (H.R. 2212, S. 974) and Fair Access for Safe and Timely (FAST) Generics Act (H.R. 2051).
Expressing support for changes to the CREATES Act (H.R. 2212, S. 974) and Fair Access for Safe and Timely (FAST) Generics Act (H.R. 2051).
Expressing support for changes to the CREATES Act (H.R. 2212, S. 974) and Fair Access for Safe and Timely (FAST) Generics Act (H.R. 2051).
Expressing support for changes to the CREATES Act (H.R. 2212, S. 974) and Fair Access for Safe and Timely (FAST) Generics Act (H.R. 2051).
Expressing support for changes to the CREATES Act (H.R. 2212, S. 974) and Fair Access for Safe and Timely (FAST) Generics Act (H.R. 2051).
Lower Drug Costs through Competition Act
Client: CELGENE CORPORATION · Firm: COVINGTON & BURLING LLP
Expressing support for changes to the CREATES Act (S. 3056), Fair Access for Safe and Timely (FAST) Generics Act (H.R. 2051), Lower Drug Costs through Competition Act (H.R. 749) and Senate counterpart (S. 297, Increasing Competition in Pharmaceuticals Act), and Affordable and Safe Prescription Drug Importation Act (S. 469).
Increasing Competition in Pharmaceuticals Act
Client: CELGENE CORPORATION · Firm: COVINGTON & BURLING LLP
Expressing support for changes to the CREATES Act (S. 3056), Fair Access for Safe and Timely (FAST) Generics Act (H.R. 2051), Lower Drug Costs through Competition Act (H.R. 749) and Senate counterpart (S. 297, Increasing Competition in Pharmaceuticals Act), and Affordable and Safe Prescription Drug Importation Act (S. 469).
North American Energy Infrastructure Act
Client: CELGENE CORPORATION · Firm: COVINGTON & BURLING LLP
Expressing support for changes to the CREATES Act (S. 3056), Fair Access for Safe and Timely (FAST) Generics Act (H.R. 2051), Lower Drug Costs through Competition Act (H.R. 749) and Senate counterpart (S. 297, Increasing Competition in Pharmaceuticals Act), and Affordable and Safe Prescription Drug Importation Act (S. 469).
Affordable and Safe Prescription Drug Importation Act
Client: CELGENE CORPORATION · Firm: COVINGTON & BURLING LLP
Expressing support for changes to the CREATES Act (S. 3056), Fair Access for Safe and Timely (FAST) Generics Act (H.R. 2051), Lower Drug Costs through Competition Act (H.R. 749) and Senate counterpart (S. 297, Increasing Competition in Pharmaceuticals Act), and Affordable and Safe Prescription Drug Importation Act (S. 469).
Creating and Restoring Equal Access to Equivalent Samples Act of 2018
Client: CELGENE CORPORATION · Firm: COVINGTON & BURLING LLP
Expressing support for changes to the CREATES Act (H.R. 2212, S. 974) and Fair Access for Safe and Timely (FAST) Generics Act (H.R. 2051).
Creating and Restoring Equal Access to Equivalent Samples Act of 2018
Client: CELGENE CORPORATION · Firm: COVINGTON & BURLING LLP
Expressing support for changes to the CREATES Act (H.R. 2212, S. 974) and Fair Access for Safe and Timely (FAST) Generics Act (H.R. 2051).
Creating and Restoring Equal Access to Equivalent Samples Act of 2018
Client: CELGENE CORPORATION · Firm: COVINGTON & BURLING LLP
Expressing support for changes to the CREATES Act (H.R. 2212, S. 974) and Fair Access for Safe and Timely (FAST) Generics Act (H.R. 2051).
Expressing support for changes to the CREATES Act (H.R. 2212, S. 974) and Fair Access for Safe and Timely (FAST) Generics Act (H.R. 2051).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CELGENE CORPORATION via COVINGTON & BURLING LLP
2018 · second_quarter · Q2
Expressing support for changes to the CREATES Act (H.R. 2212, S. 974) and Fair Access for Safe and Timely (FAST) Generics Act (H.R. 2051). Analyzing the impact of SOUND Disposal and Packaging Act (HR 5687), the Opioid Crisis Response Act of 2018 (S. 2680), and the Stop Counterfeit Drugs by Regulating and Enhancing Enforcement Now Act" (the "SCREEN Act"), H.R. 5228.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CELGENE CORPORATION via COVINGTON & BURLING LLP
2018 · first_quarter · Q1
Expressing support for changes to the CREATES Act (H.R. 2212, S. 974) and Fair Access for Safe and Timely (FAST) Generics Act (H.R. 2051).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CELGENE CORPORATION via COVINGTON & BURLING LLP
2017 · fourth_quarter · Q4
Expressing support for changes to the CREATES Act (H.R. 2212, S. 974) and Fair Access for Safe and Timely (FAST) Generics Act (H.R. 2051).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CELGENE CORPORATION via COVINGTON & BURLING LLP
2017 · third_quarter · Q3
Expressing support for changes to the CREATES Act (H.R. 2212, S. 974) and Fair Access for Safe and Timely (FAST) Generics Act (H.R. 2051).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CELGENE CORPORATION via COVINGTON & BURLING LLP
2017 · second_quarter · Q2
Expressing support for changes to the CREATES Act (H.R. 2212, S. 974) and Fair Access for Safe and Timely (FAST) Generics Act (H.R. 2051).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CELGENE CORPORATION via COVINGTON & BURLING LLP
2017 · first_quarter · Q1
Expressing support for changes to the CREATES Act (S. 3056), Fair Access for Safe and Timely (FAST) Generics Act (H.R. 2051), Lower Drug Costs through Competition Act (H.R. 749) and Senate counterpart (S. 297, Increasing Competition in Pharmaceuticals Act), and Affordable and Safe Prescription Drug Importation Act (S. 469).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE